Inter-individual variability in the oxidation of 1,2-dibromoethane: Use of heterologously expressed human cytochrome P450 and human liver microsomes

Chemico-Biological Interactions

Volumn 101, Issue 3, 1996, Pages 175-192

  Wormhoudt, Lars W ^a   Ploemen, Jan H T M ^b   De Waziers, Isabelle ^c   Commandeur, Jan N M ^a   Beaune, Philippe H ^c   Van Bladeren, Peter J ^b   Vermeulen, Nico P E ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b TNO   (Netherlands)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

1,2 Dibromoethane (ethylene dibromide); CYP2A6; CYP2B6; CYP2E1; Heterologously expressed P450s; Human liver microsomes; Inter individual variability

Indexed keywords

1,2 DIBROMOETHANE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME;

AEROBIC METABOLISM; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER METABOLISM; LIVER MICROSOME; NORMAL HUMAN;

EID: 0030572720     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-2797(96)03723-4     Document Type: Article

References (64)

1. [1] S.A. Wrighton and J.C. Stevens, The human hepatic cytochromes P450 involved in drug metabolism, Crit. Rev. Toxicol., 22 (1992) 1-21.
2. [2] A.R. Goeptar, H. Scheerens and N.P.E. Vermeulen, Oxygen and xenobiotic reductase activities of cytochrome P450, Crit. Rev. Toxicol., 25 (1995) 25-65.
3. [3] D.R. Nelson, L. Koymans, T. Kamataki, J.J. Stegeman, R. Feyereisen, D.J. Waxman, M.R. Waterman, O. Gotoh, M.J. Coon, R.W. Estabrook, I.C. Gunsalus and D.W. Nebert, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics, 6 (1996) 1-42.
4. [4] T. Shimada, H. Yamazaki, M. Mimura, Y. Inui and F.P. Guengerich, Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians, J. Pharmacol. Exp. Ther., 270 (1994) 414-423.
5. [5] L.M. Forrester, C.J. Henderson, M.J. Glancey, D.J. Back, B.K. Park, S.E. Ball, N.R. Kitteringham, A.W. McLaren, J.S. Miles, P. Skett and C.R. Wolf, Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics, Biochem. J., 281 (1992) 359-368.
6. [6] A.B. Okey, Enzyme induction in the cytochrome P450 system, Pharmac. Ther., 45 (1990) 241-298.
7. [7] C.A.D. Smith, G. Smith and C.R. Wolf, Genetic polymorphisms in xenobiotic metabolism, Eur. J. Cancer, 30A (1994) 1921-1935.
8. [8] G.V. Alexeeff, W.W. Kilgore, and M.-Y. Li, Ethylene dibromide: toxicology and risk assessment, Rev. Environ. Contam. Toxicol., 112 (1990) 49-122.
9. [9] U. Rannug, Genotoxic effects of 1,2-dibromoethane and 1,2-dichloroethane, Mutat. Res., 76 (1980) 269-295.
10. [10] P.J. van Bladeren, D.D. Breimer, G.M.T. Rotteveel-Smijs, R.A.W. de Jong, W. Buijs, A. van der Gen and G.R. Mohn, The role of glutathione conjugation in the mutagenicity of 1,2-dibromoethane, Biochem. Pharmacol., 29 (1980) 2975-2982.
11. [11] J.C. Ramsey, C.N. Park, M.G. Ott and P.J. Gehring, Carcinogenic risk assessment: ethylene dibromide, Toxicol. Appl. Pharmacol., 47 (1979) 411-414.
12. [12] M.G. Ott, H.C. Scharnweber and R.R. Langner, Mortality experience of 161 employees exposed to ethylene dibromide in two production units, Br. J. Ind. Med., 37 (1980) 163-168.
13. [13] P.J. van Bladeren, D.D. Breimer, J.A.T.C.M. van Huijgevoort, N.P.E. Vermeulen and A. van der Gen, The metabolic formation of N-acetyl-S-2-hydroxyethyl-L-cysteine from tetradeutero-1,2-dibromoethane: relative importance of oxidation and glutathione conjugation in vivo, Biochem. Pharmacol., 30 (1981) 2499-2502.
14. 7-Guanyl)ethyl)glutathione in DNA, J. Am. Chem. Soc., 110 (1988) 3284-3291.
15. [15] D.L. Hill, T.-W. Shih, T.P. Johnston, and R.F. Struck, Macromolecular binding and metabolism of the carcinogen 1,2-dibromoethane, Cancer Res., 38 (1978) 2438-2442.
16. [16] N.P.E. Vermeulen, Analysis of mercapturic acids as a tool in biotransformation, biomonitoring and toxicological studies, Trends Pharmacol. Sci., 10 (1989) 177-181.
17. [17] F.P. Guengerich, D.-H. Kim and M. Iwasaki, Role of human cytochrome P450 IIE1 in the oxidation of many low molecular weight cancer suspects, Chem. Res. Toxicol., 4 (1991) 168-179.
18. [18] L.W. Wormhoudt, J.H.T.M. Ploemen, J.N.M. Commandeur, B. van Ommen, P.J. van Bladeren and N.P.E. Vermeulen, Cytochrome P450 catalyzed metabolism of 1,2-dibromoethane in liver microsomes of differentially induced rats, Chem.-Biol. Interact., 99 (1996) 41-53.
19. [19] D.R. Koop, B.L. Crump, G.D. Nordblom and M.J. Coon, Immunochemical evidence for the induction of the alcohol-oxidizing cytochrome P450 of rabbit liver microsomes by diverse agents: ethanol, imidazole, trichloroethylene, acetone, pyrazole and isoniazid, Proc. Natl. Acad. Sci. USA, 82 (1985) 4065-4069.
20. [20] L. Koymans, G.M. Donné-Op den Kelder, J.M. te Koppele and N.P.E. Vermeulen, Cytochromes P450: Their active-site structure and mechanism of oxidation, Drug. Metab. Rev., 25 (1993) 325-387.
21. [21] K.R. Korzekwa and J.P. Jones, Predicting the cytochrome P450 mediated metabolism of xenobiotics, Pharmacogenetics, 3 (1993) 1-18.
22. [22] J.O. Miners, M.E. Veronese and D.J. Birkett, In vitro approaches for the prediction of human drug metabolism, Ann. Report. Med. Chem., 29 (1994) 307-316.
23. [23] M. Shou, K.R. Korzekwa, C.L. Crespi, F.J. Gonzalez and H.V. Gelboin, The role of 12 cDNA expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene trans-7,8-dihydrodiol, Mol. Carcinogen., 10 (1994) 159-168.
24. [24] T. Nakajima, E. Elovaara, F.J. Gonzalez, H.V. Gelboin, H. Raunio, O. Pelkonen, H. Vainio and T. Aoyama, Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450, Chem. Res. Toxicol., 7 (1994) 891-896.
25. [25] H.R. Ha, J. Chen, A.U. Freiburghaus and F. Follath, Metabolism of theophylline by cDNA-expressed human cytochromes P-450, Br. J. Clin. Pharmac., 39 (1995) 321-326.
26. [26] D.J. Newton, R.W. Wang and A.Y.H. Lu, Cytochrome P450 inhibitors; Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes, Drug Metab. Dispos., 23 (1995) 154-158.
27. [27] J.R. Halpert, F.P. Guengerich, J.R. Bend and M.A. Correia, Selective inhibitors of cytochromes P450, Toxicol. Appl. Pharmacol., 125 (1994) 163-175.
28. [28] J.J.P. Bogaards, B. van Ommen, C.R. Wolf and P.J. van Bladeren, Human cytochrome P450 enzyme selectivities in the oxidation of chlorinated benzenes, Toxicol. Appl. Pharmacol., 132 (1995) 44-52.
29. [29] K. Yoshimoto, H. Echizen, K. Chiba, M. Tani and T. Ishizaki, Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-N-deisopropylation is mediated mainly by CYP1A2, Br. J. Clin. Pharmac., 39 (1995) 421-431.
30. [30] C.L. Crespi, R. Langenbach and B.W. Penman, Human cell lines, derived from AHH-1 TK ± human lymphoblasts, genetically engineered for expression of cytochromes P450, Toxicology, 82 (1993) 89-104.
31. [31] P. Urban, C. Cullin and D. Pompon, Maximizing the expression of mammalian cytochrome P-450 monooxygenase activities in yeast cells, Biochimie, 72 (1990) 463-472.
32. [32] J.-C. Gautier, P. Urban, P. Beaune and D. Pompon, Engineered yeast cells as model to study coupling between human xenobiotic metabolizing enzymes: Simulation of the two first steps of benzo[a]pyrene activation, Eur. J. Biochem., 211 (1993) 63-72.
33. 5, Gene, 125 (1993) 49-55.
34. 5, Eur. J. Biochem., 207 (1992) 109-116.
35. [35] P. Kremers, P. Beaune, T. Cresteil, J. De Graeve, S. Columelli, J.-P. Leroux and J.E. Gielen, Cytochrome P-450 monooxygenase activities in human and rat liver microsomes, Eur. J. Biochem., 118 (1981) 599-606.
36. [36] E. Neau, P.M. Dansette, V. Andronik and D. Mansuy, Hydroxylation of the thiophene ring by hepatic monooxygenases. Evidence for 5-hydroxylation of 2-aroylthiophenes as a general metabolic pathway using a simple UV-visible assay, Biochem. Pharmacol., 39 (1990) 1101-1107.
37. [37] R. Peter, R. Böcker, P.H. Beaune, M. Iwasaki, F.P. Guengerich and C.S. Yang, Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1, Chem. Res. Toxicol., 3 (1990) 566-573.
38. [38] V. Carrière, T. Goasduff, D. Ratanasavanh, F. Morel, J.-C. Gautier, A. Guillouzo, P. Beaune and F. Berthou, Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone, Chem. Res. Toxicol., 6 (1993) 852-857.
39. [39] J.F. Newton, W.E. Braselton Jr., L.F. Lepper, K.M. McCormack and J.B. Hook, Rapid separation of testosterone and its microsomal metabolites by reverse-phase high performance liquid chromatography, J. Liquid Chromatogr., 5 (1982) 563-570.
40. [40] M.A. Leo, S. Iida and C.S. Lieber, Retinoic acid metabolism by a system reconstituted with cytochrome P-450, Arch. Biochem. Biophys., 234 (1984) 305-312.
41. [41] R.A. Lubet, R.T. Mayer, J.W. Cameron, R.W. Nims, M.D. Burke, T. Wolff and F.P. Guengerich, Dealkylation of pentoxyresorufin: A rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat, Arch. Biochem. Biophys., 238 (1985) 43-48.
42. [42] J.G. DeLuca, G.R. Dysart, D. Rasnick and M.O. Bradley, A direct, highly sensitive assay for cytochrome P-450 catalyzed O-deethylation using a novel coumarin analog, Biochem. pharmacol., 37 (1988) 1731-1739.
43. [43] R. Pearce, D. Greenway and A. Parkinson, Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: Effects on coumarin, dicumarol, and testosterone oxidation, Arch. Biochem. Biophys., 298 (1992) 211-225.
44. [44] S.A. Wrighton, P. Maurel, E.G. Schuetz, P.B. Watkins, B. Young and P.S. Guzelian, Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p, Biochemistry, 24 (1985) 2171-2178.
45. [45] T. Nash, The colorimetric estimation of formaldehyde by means of the Hantzsch reaction, Biochem. J., 55 (1953)416-421.
46. [46] D.R. Koop, Hydroxylation of p-nitrophenol by rabbit ethanol-inducible cytochrome P-450 isozyme 3a, Mol. Pharmacol., 29 (1986) 399-404.
47. [47] C. Belloc, S. Baird, J. Cosme, S. Lecoeur, J.-C. Gautier, D. Challine, I de Waziers, J.-P. Flinois and P.H. Beaune, Human cytochromes P-450 expressed in Escherichia coli: production of specific antibodies, Toxicology, 106 (1996) 207-219.
48. [48] M.D. Burke, S. Thompson, R.J. Weaver, C.R. Wolf and R.T. Mayer, Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver, Biochem. Pharmacol., 48 (1994) 923-936.
49. [49] M.A. Leo, J.M. Lasker, J.L. Raucy, C-I. Kim, M. Black and C.S. Lieber, Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8, Arch. Biochem. Biophys., 269 (1989) 305-312.
50. [50] H. Yamazaki, Z. Guo and F.P. Guengerich, Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation, Drug Metab. Dispos., 23 (1995) 438-440.
51. [51] S. Ono, T. Hatanaka, H. Hotta, M. Tsutsui, T. Satoh and F.J. Gonzalez, Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1, Pharmacogenetics, 5 (1995) 143-150.
52. [52] V. Carrière, F. Berthou, S. Baird, C. Belloc, P. Beaune and I. de Waziers, Human cytochrome P450 2E1 (CYP2E1): From genotype to phenotype, (in press).
53. [53] E. Eliasson, S. Mkrtchian and M. Ingelman-Sundberg, Hormone- and substrate-regulated intracellular degradation of cytochrome P450 (2E1) involving MgATP-activated rapid proteolysis in the endoplasmatic reticulum membranes, J. Biol. Chem., 267 (1992) 15765-15769.
54. [54] W. Tassaneeyakul, M.E. Veronese, D.J. Birkett, F.J. Gonzalez and J.O. Miners, Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques, Biochem. Pharmacol., 46 (1993) 1975-1981.
55. [55] R.B. Kim, D. O'Shea and G.R. Wilkinson, Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms, Clin. Pharmacol. Ther., 57 (1995) 645-655.
56. [56] E.S. Vesell, T. DeAngelo Seaton and Y.I. A-Rahim, Studies on interindividual variations of CYP2E1 using chlorzoxazone as an in vivo probe, Pharmacogenetics, 5 (1995) 53-57.
57. [57] S.G. Kim and R.F. Novak, The induction of cytochrome P4502E1 by nitrogen- and sulfur-containing heterocycles: Expression and molecular regulation, Toxicol. Appl. Pharmacol., 120 (1993) 257-265.
58. [58] D. O'Shea, S.N. Davis, R.B. Kim and G.R. Wilkinson, Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity, Clin. Pharmacol. Ther., 56 (1994) 359-367.
59. [59] B.J. Song, R.L. Veech and P. Saenger, Cytochrome P450IIE1 is elevated in lymphocytes from poorly controlled insulin-dependent diabetics, J. Clin. Endocrinol. Metab., 71 (1990) 1036-1040.
60. [60] S.-I. Hayashi, J. Watanabe and K. Kawajiri, Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene, J. Biochem., 110 (1991) 559-565.
61. [61] J. Watanabe, S.-I. Hayashi and K. Kawajiri, Different regulation and expression of the human CYP2E1 gene due to the Rsa I polymorphism in the 5′-flanking region, J. Biochem., 116 (1994) 321-326.
62. [62] F. Uematsu, S. Ikawa, H. Kikuchi, I. Sagami, R. Kanamaru, T. Abe, K. Satoh, M. Motomiya and M. Watanabe, Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure, Pharmacogenetics, 4 (1994) 58-63.
63. [63] J.H.T.M. Ploemen, L.W. Wormhoudt, B. van Ommen, J.N.M. Commandeur, N.P.E. Vermeulen and P.J. van Bladeren, Polymorphism in the glutathione conjugation activity of human erythrocytes towards ethylene dibromide and 1,2-epoxy-3-(p-nitrophenoxy)-propane, Biochim. Biophys. Acta, 1243 (1995) 469-476.
64. [64] S. Pemble, K.R. Schroeder, S.R. Spencer, D.J. Meyer, E. Hallier, H.M. Bolt, B. Ketterer and J.B. Taylor. Human glutathione S-Transferase Theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism, Biochem. J., 300 (1994) 271-276.